Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial Article

Lassman, Andrew B, Polley, Mei-Yin C, Iwamoto, Fabio M et al. (2025). Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial . JOURNAL OF CLINICAL ONCOLOGY, 43(27), 10.1200/JCO-25-00618

cited authors

  • Lassman, Andrew B; Polley, Mei-Yin C; Iwamoto, Fabio M; Sloan, Andrew E; Wang, Tony JC; Aldape, Kenneth D; Wefel, Jeffrey S; Gondi, Vinai; Gutierrez, Alonso N; Manasawala, Mohammed H; Gilbert, Mark R; Sulman, Erik P; Wolchok, Jedd D; Green, Richard M; Neil, Elizabeth C; Lukas, Rimas V; Goldlust, Samuel A; Snuderl, Matija; Galbraith, Kristyn; Dignam, James J; Won, Minhee; Mehta, Minesh P

sustainable development goals

authors

publication date

  • September 20, 2025

published in

keywords

  • ADJUVANT TEMOZOLOMIDE
  • CENTRAL-NERVOUS-SYSTEM
  • CLASSIFICATION
  • CONCOMITANT
  • GLIOMAS
  • IPILIMUMAB
  • Life Sciences & Biomedicine
  • NIVOLUMAB
  • Oncology
  • RADIOTHERAPY
  • RESPONSE ASSESSMENT
  • SURVIVAL
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • LIPPINCOTT WILLIAMS & WILKINS

volume

  • 43

issue

  • 27